Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
221-240 of 998 trials

Advanced Non-Squamous NSCLC: Dato-DXd with Rilvegostomig

We are studying if a new treatment combination is safe and effective compared to pembrolizumab for patients with advanced non-squamous lung cancer. This trial is for those with high PD-L1 levels and no specific genetic changes.

Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Pulmonary Arterial Hypertension: Treprostinil Sodium for Kids

We are studying the safety and tolerability of a new preservative-free medication for children with pulmonary arterial hypertension. The trial also looks at how it may improve their quality of life and symptoms.

Pulmonary Arterial Hypertension3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemotePediatricsPulmonology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Colorectal Cancer: ABBV-400 Treatment Study

We are studying a new drug, ABBV-400, combined with standard treatments for adults with advanced colorectal cancer. The goal is to assess its safety and effectiveness in patients who have already been treated.

Metastatic Colorectal CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Atopic Dermatitis: PF-07275315 and PF-07264660

We are investigating two new treatments for adults with moderate to severe atopic dermatitis. The study aims to see if they are more effective than a placebo in reducing eczema symptoms.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsCost ReimbursementPartially RemoteAllergologyDermatology

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia

We are comparing a new treatment, bomedemstat, to hydroxyurea in people with essential thrombocythemia who haven't been treated before. The goal is to see which treatment better reduces symptoms and fatigue.

Essential Thrombocythemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHematology

High-Risk Retroperitoneal Sarcoma: Chemotherapy Before Surgery

We are testing whether chemotherapy before surgery improves outcomes for patients with high-risk retroperitoneal sarcoma. This study compares the effects of preoperative chemotherapy to surgery alone.

Dedifferentiated LiposarcomaLeiomyosarcoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Treatment-Resistant Depression: COMP360 Study

We are studying whether two doses of COMP360 can improve symptoms in adults with treatment-resistant depression. This trial includes psychological support to enhance treatment effects.

Major Depressive DisorderTreatment-Resistant Depression6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Non-Hodgkin Lymphoma: Epcoritamab with Anti-Cancer Agents

We are studying the safety and tolerability of Epcoritamab combined with other anti-cancer medications for people with Non-Hodgkin Lymphoma. This trial aims to see how well this combination works and to find the best dose for future studies.

B-cell Non-Hodgkin's LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Heart Attack Prevention: Selatogrel Study

We are studying whether self-administering selatogrel can help prevent further heart attacks in individuals with a recent heart attack history. The trial also looks at the safety of this self-administration.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Primary Aldosteronism: [68Ga]Ga-PentixaFor PET Imaging Study

We are evaluating a new imaging method to help identify how adrenal glands secrete aldosterone in patients with primary aldosteronism. This may improve diagnosis and treatment options for those affected.

Primary Hyperaldosteronism>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Psilocybin for Cancer-Related Depression

We are studying whether a single dose of psilocybin can help improve mood in adults aged 20-80 with major depression after a cancer diagnosis. Participants will compare its effects to a lower dose to assess changes in depressive symptoms.

Malignant TumorsMajor Depressive Disorder6-12 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteOncologyPsychiatry